Abstract: Objective：To evaluate the clinical efficacy of Kangfuxin combined with basic fibroblast growth factor in the treatment of chronic wound. Methods：A total of 60 patients with chronic wound were randomly divided into 3 groups with 20 patients in each group: Kangfuxin group, basic fibroblast growth factor group, and combined group. The wound healing rate and clinical efficacy in each group was evaluate and compared 3 weeks after treatment. The wound exudates in each group were continuously collected during the period of treatment wound exudate, and the IL-2 levels in wound exudates were measured by ELISA in each group. Results：The wound healing duration was significantly shorter in combined group than that in either Kangfuxin group or basic fibroblast growth factor group. The clinical efficacy in combined group was higher than that in either Kangfuxin group or basic fibroblast growth factor group (P<0.05). Additionally, the IL-2 level in combined group was significantly higher than that in either Kangfuxin group or basic fibroblast growth factor group 3 days after the treatment (P<0.05). Conclusions：The combined treatment of Kangfuxin and basic fibroblast growth factor is effective in improving the healing efficacy of chronic wound.